PEPCLUB.me

Metabolic HealthWeight ManagementCardiovascular HealthBody CompositionArticleFree

Retatrutide

10mg Vial

20mg Vial

30mg Vial

40mg Vial

60mg Vial

2 July 2026Updated 18 September 2026

Retatrutide

Overview Research16

Mechanism Protocols Safety Discussions

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

16 Published Studies

Scientific literature related to Retatrutide and its potential applications.

Full text analysed

Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.

An unverified online-sourced product marketed as retatrutide was temporally associated with acute gastrointestinal illness, significant ketonaemia and AKI in a person with type 1 diabetes, but a confirmed Shigella flexneri infection and unanalysed product composition mean causation cannot be established; the case highlights diagnostic and management challenges when patients obtain unregulated peptides.

Clinical safety and adverse-effect profile of retatrutide in humans (especially those with type 1 diabetes)Interactions between incretin/glucagon receptor agonists and infectious gastrointestinal diseaseImpact of recent glucagon receptor agonist exposure on effectiveness of emergency glucagon rescue+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.7759/cureus.115260

Published

2026

Full text analysed

Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.

A probable adverse reaction (nausea, vomiting, diarrhoea) occurred after dose-escalated, unverified subcutaneous injections reported to contain retatrutide; product identity and dose were not confirmed, highlighting diagnostic and safety challenges when pharmacologically active peptides are obtained and administered outside regulated medical pathways.

Pharmacovigilance and safety of peptides and investigational metabolic agents circulating in wellness/online marketsClinical history-taking practices to capture non-prescribed injections and wellness productsAnalytical verification of unregulated products sold as investigational drugs (composition, potency, sterility, contaminants)+1 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1136/bcr-2026-276106

Published

2026

Full text analysed

Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.

In mouse models of non-diabetic renal fibrosis (UUO and aging), retatrutide produced the strongest anti-fibrotic and renoprotective effects among semaglutide, tirzepatide, and retatrutide at the tested mass dose. The three agents share PI3K-AKT inhibition and mitigation of G2/M arrest in aging, while tirzepatide engages PPAR activation and retatrutide additionally inhibits NF-κB; these pathway differences correlate with graded efficacy. Translation to humans requires further studies including dose-equivalence, pharmacokinetics, safety assessment, and clinical trials.

Renal fibrosis mechanismsGLP-1/GIP/GCGR multi-agonist pharmacologyCell-cycle regulation in kidney aging (G2/M transition)+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1016/j.isci.2026.117174

Published

2026

Abstract analysed

Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Meta-analysis of randomized controlled trials reported that retatrutide treatment lowers systolic and diastolic blood pressure and reduces total cholesterol, LDL-C, and triglycerides, with no effect on HDL-C; however, trial-level details and safety data are not provided in the abstract.

Blood pressure effects of metabolic therapeuticsLipid profile modulation by incretin/glucagon receptor agonistsCardiometabolic risk reduction with multi-receptor agonists

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1007/s40292-026-00812-6

Published

2026

Full text analysed

The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?

There is mechanistic plausibility and observational signals that incretin-based therapies could influence iron handling or lead to coded nutritional deficiencies and occasional anemia diagnoses, but current evidence is indirect and very low certainty. For retatrutide specifically, no direct clinical evidence establishes hematological harm or benefit; prospective studies with predefined hematological and micronutrient endpoints are needed.

Prospective clinical trials with predefined hematological and iron-status endpoints for retatrutide and other incretin agentsMechanistic human studies measuring hepcidin–ferroportin axis, iron absorption, and erythropoiesis during incretin therapyLongitudinal nutritional assessments and microbiome studies in patients undergoing potent incretin-induced weight loss+2 more

Relevance

80%

Source

Europe PMC, PubMed

DOI: 10.3390/medsci14050577

Published

2026

Abstract analysed

Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

In this phase 3 randomized trial in adults with obesity without diabetes, once-weekly retatrutide (4–12 mg) produced large mean weight reductions over 80 weeks (up to ~25% at 12 mg) versus placebo and improved knee pain and apnea-hypopnea index in relevant subgroups; safety details are not reported in the provided abstract.

Pharmacotherapy for obesityObesity-related knee osteoarthritis pain managementObstructive sleep apnea improvement with weight-loss therapies+1 more

Relevance

100%

Source

Europe PMC, PubMed

DOI: 10.1056/nejmoa2604169

Published

2026

Abstract analysed

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.

In diet-induced obese male rats, daily co-administration of retatrutide and cagrilintide produced dose-dependent, greater weight loss and improvements in metabolic markers than monotherapies or comparator combinations; multi-omic data suggest involvement of bioenergetic processes and central neuronal programmes, but findings are preclinical and abstract-level with limited methodological detail.

Obesity pharmacotherapyMulti-receptor peptide agonistsMetabolic disease (insulin, lipids)+2 more

Relevance

100%

Source

Europe PMC, PubMed

DOI: 10.1038/s42255-026-01603-y

Published

2026

Abstract analysed

Future GLP-1 receptor co-agonists and their cardiac effects.

The review discusses known or predicted cardiac contractile effects of GLP-1R co-agonists including retatrutide, highlights that mouse preclinical studies may not reliably predict human cardiac responses due to species-dependent receptor expression, and identifies research needs and design improvements for future preclinical work.

Cardiac contractility effects of GLP-1R co-agonistsComparative preclinical-to-human translational studiesReceptor expression profiling in heart across species+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1007/s00210-026-05908-3

Published

2026

Full text analysed

Detection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis.

In this small elimination study, intact retatrutide (LY3437943) was reliably detected in plasma by LC-HRMS with PRM confirmation for at least 56 days after two 2 mg SC doses, whereas neither the parent peptide nor predicted metabolites were detectable in urine despite multiple analytical approaches—supporting plasma (or blood-based) matrices as more appropriate than urine for antidoping detection of this lipidated, albumin-binding peptide.

Antidoping analytical method developmentPharmacokinetics of long-acting lipidated peptide therapeuticsMatrix selection for peptide detection (plasma vs urine vs blood spots)+2 more

Relevance

100%

Source

Europe PMC, PubMed

DOI: 10.1002/rcm.70179

Published

2026

Full text analysed

Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.

In two phase 2 randomized, double-blind trials in adults with obesity/overweight (with or without T2D), once-weekly retatrutide was associated with dose-dependent and substantial improvements in atherogenic lipoprotein biomarkers (non-HDL-C, ApoB, TRL-C, ApoC-III, TRLP and LDLP subclasses) and reductions in inflammatory markers (CRP, IL-6) in participants without T2D. These are surrogate markers suggestive of potential cardiovascular benefit, but clinical event data are required.

Prospective cardiovascular outcomes trials to determine whether biomarker improvements translate to reduced major adverse cardiovascular events (e.g., TRIUMPH-OUTCOMES trial NCT06383390).Longer-term studies to assess durability of lipid and inflammatory biomarker improvements during extended retatrutide treatment.Mechanistic studies to dissect weight-dependent versus weight-independent effects (e.g., mediation analyses, mechanistic biomarkers).+2 more

Relevance

95%

Source

Europe PMC, PubMed

DOI: 10.1111/dom.71200

Published

2026